Biocon Ltd share price logo

Biocon Ltd Share Price (BIOCON)


Get free price alerts. Set up your Free investment account to get Live Prices. >
Q3 '23 Results
News and Events

Overview of Biocon Ltd

Key events for Biocon Ltd

  • Biocon Pivots to Anti-Obesity Therapies Amid Patent Expirations - 08 Apr, 2024

    Biocon Ltd is leading Indian drugmakers in the race to grab a slice of the $100 billion obesity drugs market, as patents for blockbuster medications start to expire. Biocon has scored an early win among its peers with UK approval for the first generic version of liraglutide injectable.

  • Biocon Transfers Branded Formulations Business to Eris Lifesciences - 03 Apr, 2024

    Biocon Biologics has completed the transfer of its branded formulations business in India to Eris Lifesciences for Rs 1,242 crore. The transaction was conducted on a slump sale basis and includes metabolics, oncology, and critical care diagnostics.

  • Biocon Receives Approval for gSaxenda Formulation - 01 Apr, 2024

    Biocon's complex formulation Liraglutide (gSaxenda) has received approval from MHRA, UK, leading to a 1.7% rise in the company's stock. The pharmaceuticals and drugs sector saw investments exceeding expectations, with Biocon being one of the major beneficiaries. In Q3 FY24, Biocon reported a consolidated net profit of Rs 660 crore.

  • Biocon Receives Approval for Diabetes Drug Liraglutide in UK - 28 Mar, 2024

    Biocon Ltd has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, for its complex formulation Liraglutide used in treating Type-2 Diabetes Mellitus. The approval is an important milestone as it strengthens Biocon's leadership in delivering many firsts on complex drug products. Shares rose by over 3%. Biocon's operating revenues and profit figures have shown a stellar performance during recent financial quarters.

  • Biocon Stock Rises as Bernstein Maintains Ratings - 27 Mar, 2024

    Biocon Ltd's stock rises for the fifth consecutive day, while foreign brokerage firm Bernstein maintains its outperform and underperform ratings on major pharmaceutical companies.

  • Biocon Ltd Stock Up 1.83% on NSE - 22 Mar, 2024

    Biocon Ltd stock is up 1.83% on the NSE, trading at Rs 253.25 as of 12:49 IST. The stock has gained 22.34% in the last year compared to a 29.37% jump in NIFTY and a 59.35% jump in the Nifty Pharma index.

  • Biocon Stock Faces Resistance and Likely to Decline Further - 21 Mar, 2024

    Biocon Ltd's stock has been facing strong resistance at ₹290 and is expected to decline further according to technical analysis. Traders are advised to go short on the stock with a target price of ₹240.

  • Biocon Ltd Shows Strong Growth in EPS, EBIT Margins and Revenues - 20 Mar, 2024

    Biocon Ltd has shown impressive growth in EPS, with a compound annual growth rate of 26% over the last three years. Additionally, EBIT margins have grown from 12% to 14% in the past year, while revenues are on an upward trend. Insiders own a significant share of the company at 63%.

  • Biocon Collaborates with Eris Lifesciences; No Political Donations Made - 18 Mar, 2024

    Biocon has entered into a long-term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of products in India. Additionally, Kiran Mazumdar-Shaw clarified that she made political donations in her personal capacity, and Biocon did not make any political donations.

  • Biocon Receives Donations from Infosys, Embassy Group, HCGE and Biocon Group - 17 Mar, 2024

    In 2018, Biocon received donations of Rs 1 crore from Infosys Technologies, Rs 22 crore from the Embassy Group, Rs 25 lakh from Health Care Global Enterprises, and Rs 50 lakh from Biocon. In 2019, the Biocon group donated an additional Rs 1 crore, bringing their total tally to Rs 1.5 crore.

  • Biocon Subsidiary Sells Branded Formulation Business to Eris Lifesciences - 15 Mar, 2024

    Biocon Biologics India has sold its branded formulation business to Eris Lifesciences for Rs 1,242 crore. Meanwhile, Biocon CFO Indranil Sen resigned. The transaction value represents an accretive multiple of 3.4 times revenue and 18 times EBITDA. Shares fell over 4%.

  • Eris Lifesciences Acquires Biocon's Branded Formulations Business - 14 Mar, 2024

    Eris Lifesciences has acquired Biocon Biologics India's branded formulation business for Rs 1,242 crore and signed a 10-year supply agreement with Biocon. The acquisition will facilitate Eris' entry into the injectables market in India and mark its entry into oncology and critical care.

Analyst Rating for Biocon Ltd stock

based on 19 analysts


Based on 19 analysts offering long term price targets for Biocon Ltd. An average target of ₹278.58

Source: S&P Global Market Intelligence

Biocon Ltd share Performance

  • ₹262.1
    downward going graph



    Day's Volatility:3.64%



    downward going graph
  • ₹217.5
    downward going graph



    52 Weeks Volatility:33.78%



    downward going graph
1 Month Return8.88 %
3 Month Return-2.53 %
1 Year Return22.35 %
Previous Close₹274.00
Upper Circuit-
Lower Circuit-
Market Cap₹32,896.44Cr

Biocon Ltd Company Information

Biocon Ltd is a biopharmaceutical company founded in 1978 by Kiran Mazumdar-Shaw. It is headquartered in Bangalore, India and is one of the top biopharma companies in the world. The company operates in four core areas - biopharmaceuticals, biologics, research services, and clinical research. Biocon's biopharmaceuticals business focuses on biologics and biosimilars, while its biologics business focuses on the discovery, development and commercialization of novel biologics. Its research services include contract research and manufacturing services, while its clinical research business focuses on clinical trials and clinical data management.

Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.

Share Price: ₹265.25 per share as on 15 Apr, 2024 04:01 PM
Market Capitalisation: ₹32,896.44Cr as of today
Revenue: ₹3,953.70Cr as on December 2023 (Q4 23)
Net Profit: ₹753.30Cr as on December 2023 (Q4 23)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
OrganisationBiocon Ltd
E-voting on sharesClick here to vote

Fundamentals of Biocon Ltd

Insights on Biocon Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    Profit Spike


    Netprofit is up for the last 3 quarters, 101.4 Cr → 660.0 Cr (in ₹), with an average increase of 50.1% per quarter


    Retail Holding Up


    Retail Investor have increased holdings from 16.92% to 17.96% in Dec 2023 quarter


    Revenue Rich


    Revenue is up for the last 3 quarters, 3.51K Cr → 4.54K Cr (in ₹), with an average increase of 11.6% per quarter


    MF Holding Up


    Mutual Funds have increased holdings from 8.26% to 9.31% in Dec 2023 quarter

  • imgNO EFFECT

    Against Peers


    In the last 1 year, Shree Ganesh Remedies Ltd has given 104.1% return, outperforming this stock by 81.7%

  • imgNO EFFECT

    Against Peers


    In the last 3 years, Shree Ganesh Remedies Ltd has given 150.0% return, outperforming this stock by 182.3%

  • imgNO EFFECT

    Promoter Holding Unchanged


    Promoters holdings remained unchanged at 60.64% of holdings in Dec 2023 quarter


    Price Dip


    In the last 3 years, BIOCON stock has moved down by -32.3%


    FII Holding Down


    Foreign Institutions have decreased holdings from 7.96% to 6.55% in Dec 2023 quarter

Biocon Ltd Valuation

Biocon Ltd in the last 5 years

  • Overview

  • Trends

Lowest (24.48x)

March 19, 2024

Today (27.29x)

April 12, 2024

Industry (62.56x)

April 12, 2024

Highest (118.86x)

September 27, 2018


Biocon Ltd Mutual Fund Holdings

Funds Holdings
SBI Contra Fund Direct GrowthSBI Contra Fund Direct Growth1.65%
Mirae Asset Large Cap Fund Direct Plan GrowthMirae Asset Large Cap Fund Direct Plan Growth0.73%
SBI Balanced Advantage Fund Direct GrowthSBI Balanced Advantage Fund Direct Growth0.92%
Quant Flexi Cap Fund Growth Option Direct PlanQuant Flexi Cap Fund Growth Option Direct Plan3.21%
Quant Mid Cap Fund Growth Option Direct PlanQuant Mid Cap Fund Growth Option Direct Plan2.29%

Biocon Ltd Shareholding Pattern

InvestorsHoldings %Prev. 4 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Technicals of Biocon Ltd share

News & Events of Biocon Ltd

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Biocon Ltd shares.

Biocon Ltd (BIOCON) share price today is ₹265.25

Biocon Ltd is listed on NSE

Biocon Ltd is listed on BSE

  • Today’s highest price of Biocon Ltd is ₹271.75.
  • Today’s lowest price of Biocon Ltd is ₹262.1.

PE Ratio of Biocon Ltd is 27.29

PE ratio = Biocon Ltd Market price per share / Biocon Ltd Earnings per share

Today’s traded volume of Biocon Ltd(BIOCON) is 40.72L.

Today’s market capitalisation of Biocon Ltd(BIOCON) is ₹32896.44Cr.

Biocon Ltd(BIOCONPrice
52 Week High
52 Week Low

Biocon Ltd(BIOCON) share price is ₹265.25. It is down -13.63% from its 52 Week High price of ₹307.1

Biocon Ltd(BIOCON) share price is ₹265.25. It is up 21.95% from its 52 Week Low price of ₹217.5

Biocon Ltd(BIOCONReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns